Skip to main content
SpringerLink
Log in

Use of drugs with TdP risk in patients with long QT syndrome

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. drugs that may prolong the QT interval or induce torsades de pointes

  2. The most commonly first-prescribed TdP risk drugs were antibacterials (34.1%), proton pump inhibitors (15.0%), antidepressants (12.0%) and antifungals (10.2%).

Reference

  • Weeke PE, et al. Long-term proarrhythmic pharmacotherapy among patients with congenital long QT syndrome and risk of arrhythmia and mortality. European Heart Journal : [8 pages], 11 May 2019. Available from: URL: https://dx.doi.org/10.1093/eurheartj/ehz228

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Use of drugs with TdP risk in patients with long QT syndrome. Reactions Weekly 1754, 13 (2019). https://doi.org/10.1007/s40278-019-62246-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-019-62246-2

Search

Navigation